News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,364 Results
Type
Article (38969)
Company Profile (277)
Press Release (644118)
Section
Business (203823)
Career Advice (1985)
Deals (35358)
Drug Delivery (84)
Drug Development (80770)
Employer Resources (168)
FDA (16085)
Job Trends (14797)
News (344466)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16004)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11465)
Biotechnology (196)
Breast cancer (108)
Cancer (906)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (200)
Clinical research (63927)
Collaboration (326)
Compensation (168)
COVID-19 (2522)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6097)
Earnings (84171)
Employer resources (146)
Events (108898)
Executive appointments (248)
FDA (16530)
Funding (291)
Gene therapy (149)
GLP-1 (558)
Government (4318)
Healthcare (18654)
Infectious disease (2597)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16271)
Job creations (3622)
Job search strategy (1415)
Layoffs (408)
Legal (7848)
Lung cancer (155)
Manufacturing (152)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19109)
Metabolic disorders (364)
Neuroscience (1456)
NextGen Class of 2024 (6496)
Non-profit (4462)
Northern California (1212)
Obesity (216)
Opinion (176)
Patents (94)
People (56128)
Phase I (19828)
Phase II (28147)
Phase III (21015)
Pipeline (212)
Postmarket research (2553)
Preclinical (8430)
Radiopharmaceuticals (234)
Rare diseases (180)
Real estate (5888)
Regulatory (21441)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1085)
Startups (3560)
United States (11710)
Vaccines (537)
Weight loss (160)
Date
Today (288)
Last 7 days (845)
Last 30 days (2972)
Last 365 days (35692)
2024 (30470)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (187)
Asia (37012)
Australia (6037)
California (2741)
Canada (1180)
China (209)
Colorado (119)
Connecticut (123)
Europe (79244)
Florida (396)
Georgia (100)
Illinois (308)
Indiana (179)
Kansas (95)
Maryland (516)
Massachusetts (2248)
Michigan (144)
Minnesota (250)
New Jersey (829)
New York (842)
North Carolina (665)
Northern California (1212)
Ohio (127)
Pennsylvania (748)
South America (1091)
Southern California (1085)
Texas (385)
Utah (80)
Washington State (323)
683,364 Results for "qualigen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Qualigen Therapeutics, Inc. Announces management changes.
September 27, 2024
·
3 min read
Deals
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Qualigen Therapeutics, Inc. announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).
May 30, 2024
·
5 min read
Press Releases
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
September 20, 2024
·
2 min read
Business
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
September 6, 2024
·
4 min read
Press Releases
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
September 5, 2024
·
4 min read
Business
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
April 16, 2024
·
4 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
Biotech Beach
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 9, 2024
·
5 min read
Business
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Qualigen Therapeutics, Inc. today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update.
August 15, 2023
·
14 min read
Business
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023.
November 14, 2023
·
9 min read
1 of 68,337
Next